Research Article

Efficacy and Safety of Tongning Gel for Knee Osteoarthritis: A Multicentre, Randomized, Double-Blinded, Parallel, Placebo-Controlled, Clinical Trial

Table 1

Baseline characteristics between experimental group and control group.

VariableTNG (n = 431)PC (n = 144) value

Gender, n (%)1.0000
 Male (%)94 (21.81%)31 (21.53%)
 Female (%)337 (78.19%)113 (78.47%)
Age (years)55.44 ± 8.1654.44 ± 8.200.2035
Height (cm)162.83 ± 6.56162.43 ± 7.060.5323
Weight (kg)61.73 ± 8.1360.89 ± 8.770.2906
Heart rate (beats/min)71.69 ± 7.9971.26 ± 8.520.5787
Respiratory rate (beats/min)18.52 ± 1.5518.68 ± 1.870.3677
Systolic BP (mmHg)123.23 ± 9.29122.58 ± 10.230.4785
Diastolic BP (mmHg)77.63 ± 6.7076.95 ± 7.470.3370
Duration of KOA (months)8.00 ± 21.006.00 ± 14.000.530
Location of the disease, n (%)0.0129
 Left knee207 (48.03%)55 (38.19%)
 Right knee223 (51.74%)86 (59.72%)
 Both knees1 (0.23%)3 (2.08%)
Baseline WOMAC, mean ± SD
 Pain score183.61 ± 64.86177.36 ± 66.920.3215
 Stiffness score47.87 ± 31.5346.76 ± 32.480.7165
 Function score579.88 ± 195.62555.01 ± 202.970.1913
 Total score811.35 ± 272.16779.13 ± 281.190.2230
KL classification, n (%)0.738
 Grade 018 (4.18%)13 (9.03%)
 Grade 1116 (26.91%)32 (22.22%)
 Grade 2246 (57.08%)82 (56.94%)
 Grade 351 (11.83%)17 (11.81%)
History of treatment, n (%)1.0000
 No430 (99.77%)144 (100.00%)
 Yes1 (0.23%)0 (0.00%)
Other disease: no. of patients (%)0.7018
 No403 (93.50%)133 (92.36%)
 Yes28 (6.50%)11 (7.64%)
History of drug allergy: no. of patients (%)0.6977
 No425 (98.61%)141 (97.92%)
 Yes6 (1.39%)3 (2.08%)

Plus-minus values are means ± SD unless otherwise noted. TNG = Tongning Gel; PC = placebo-controlled. WOMAC = the Western Ontario and McMaster Universities Arthritis Index. KL classification = Kellgren–Lawrence classification.